Europe midday: Pharma stocks slide on Kennedy pick as US health chief

European equity markets trimmed losses on Friday with pharma stocks lower on news that Robert F. Kennedy Jr – who has made misleading statements on vaccines – had been appointed as Donald Trump’s head of health.

Robert Kennedy Jr

Source: Sharecast

The pan-European Stoxx 600 index was down 0.46% at 504.64.

Trump late on Thursday nominated Kennedy, who last year said he believe autism was caused by vaccines and has made a raft of other unsubstantiated statements, to lead the Department of Health and Human Services in his new administration when it takes power next January.

Pharmaceutical stocks such as GSK, Sanofi, Swedish Orphan Biovitrum, UCB, Sartorius Stedim, Zealand Pharma and Roche were all knocked by the news.

In positive news for the sector, shares in Evotec surged as the German drug developer received an €11-per-share offer from Halozyme Therapeutics, valuing the company at about €2bn.

In other equity news, Generali jumped as the Italian insurer posted better-than-expected nine-month profits.

London stocks rallied from morning losses as data showed that economic growth in the UK unexpectedly slowed in the third quarter.

Figures released earlier by the Office for National Statistics showed the economy grew by 0.1% in the last quarter, slightly below expectations.

Growth in the three months to September had been led by strength in the retail trade, excluding motor vehicles, and new construction work. Output in the construction sector jumped 0.8%.

The 0.1% uptick was, however, below second-quarter growth of 0.2%. It also missed analyst expectations for a 0.2% improvement.

Sentiment was also dampened by the European Commission cutting its economic growth forecast for the eurozone next year, and warned that projections could be reduced further in the event of increased protectionist measures – such as the import tariffs proposed by Trump.

Eurozone GDP growth is expected to pick up to 1.3% in 2025, from an estimated 0.8% this year, slightly below the Commission’s previous 1.4% forecast.

Reporting by Frank Prenesti for Sharecast.com

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Lloyds Bank is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

Lloyds and Lloyds Bank are trading names of Halifax Share Dealing Limited. The Lloyds Bank Direct Investments Service is operated by Halifax Share Dealing Limited. Registered Office: Trinity Road, Halifax, West Yorkshire, HX1 2RG. Registered in England and Wales no. 3195646. Halifax Share Dealing Limited is authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under registration number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

Logo Allfunds

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

FE fundinfo Logo

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

Refinitiv Logo

© 2025 Refinitiv, an LSEG business. All rights reserved.